Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast for moderate to severe knee osteoarthritis
IRCT20190810044500N31Phase 3Completed
- Sponsor
- Dr. Abidi Pharmaceuticals
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of apremilast in knee osteoarthritis (OA) (2 arms), sponsored by Dr. Abidi Pharmaceuticals. Primary endpoint: Change in WOMAC pain score. Started Jan 2026; status: completed.
02
Drugs
apremilast
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on IRCT20190810044500N31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190810044500N31.